NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer

PURPOSE: NY-ESO-1 cancer testis (CT) antigen is an attractive candidate for immunotherapy as a result of its high immunogenicity. The aim of this study was to explore the potential for NY-ESO-1 antigen directed immunotherapy in triple negative breast cancer (TNBC) by determining the frequency of exp...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ademuyiwa, Foluso O., Bshara, Wiam, Attwood, Kristopher, Morrison, Carl, Edge, Stephen B., Ambrosone, Christine B., O’Connor, Tracey L., Levine, Ellis G., Miliotto, Anthony, Ritter, Erika, Ritter, Gerd, Gnjatic, Sacha, Odunsi, Kunle
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2012
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3386262/
https://ncbi.nlm.nih.gov/pubmed/22761704
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0038783
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak